Humanized anti-CD19 antibody and use thereof with chimeric antigen receptor
Embodiments herein relate to humanized CD19 antibodies and disease treatment using the antibodies. For example, a subject having a CD19 positive tumor may be administered a therapeutically effective amount of the humanized antibody.
1. An isolated nucleic acid sequence encoding a humanized antibody or antigen binding fragment thereof, wherein the humanized antibody or antigen binding fragment thereof comprising a heavy chain variable (HCV) sequence having the amino acid sequence of SEQ ID NO: 27, and a light chain variable (LCV) sequence having the amino acid sequence of SEQ ID NO: 37.
2. The isolated nucleic acid sequence of claim 1 , wherein the antigen binding fragment is selected from the group consisting of a Fab, Fab′, Fab′-SH, Fv, scFv, F(ab)2 and a diabody.
3. A vector comprising the isolated nucleic acid sequence of claim 1 .
4. An isolated cell comprising the vector of claim 3 .
5. The vector of claim 3 , wherein the vector is an expression vector comprising control sequences operably linked to the isolated nucleic acid.
6. A composition comprising a population of the cells of claim 4 .
7. The composition of claim 6 , wherein the cells are T cells.
8. The composition of claim 7 , wherein the composition is a pharmaceutical composition.
9. An isolated host cell comprising the expression vector of claim 5 .
10. A composition comprising a population of the cells of claim 9 .
11. The composition of claim 10 , wherein the cells are T cells.
12. The composition of claim 11 , wherein the composition is a pharmaceutical composition.